Medigene AG to Discuss TCR-T Therapy for Solid Tumors Transcript
Hello, and welcome to the Medigene R&D event. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the Medigene website following the conclusion of the event. I'd now like to turn the call over to your host, Selwyn Ho, CEO of Medigene. Please go ahead, Selwyn.
Good morning. Good afternoon to all of you. My name is Selwyn Ho, and I'm the CEO of Medigene and thank you for joining us today at Medigene's R&D event where we'll be discussing Medigene's approach to the development of TCR-T therapies for solid tumors.
Here's the agenda for our event. In over approximately the next hour, members of our R&D and corporate leadership teams will be discussing a number of topics. Firstly, our focus on patients and the need in solid tumors.
Secondly, what could be the ideal adoptive cell therapy for solid tumors?
Next up would be our end-to-end platform as the basis of our approach to generate optimal TCRs and ultimately, we believe highly differentiated
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
